A cutting-edge immunotherapy technique called CAR-T cell Therapy Treatment is intended to cure a variety of malignancies, including blood diseases like leukemia and lymphoma. Through genetic modification, a patient’s T cells are better able to identify and combat cancer cells.
Patients with relapsed or refractory tumors—especially B-cell cancers like lymphoma, leukemia, and multiple myeloma—who have not responded to standard treatments like chemotherapy or radiation are typically candidates for CAR-T therapy. Leukapheresis, in which T cells are isolated from the patient’s blood via apheresis, is the first step in the procedure. Usually, this process takes two to four hours.
FOR MORE INFORMATION CLICK HERE âž– https://www.edhacare.com/treatments/cancer/car-t-cell-therapy
After being harvested, the T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) on their surface in a specialist lab. The purpose of the CAR is to identify particular antigens found on cancer cells, such as CD19 in B-cell lymphomas. The T cells’ capacity to precisely target and eliminate tumor cells is improved by this alteration.
Following genetic alteration, the T cells are infused into the patient after being massively increased in the lab. It takes a few days to a few weeks. Now, when the CAR-T cells are reintroduced, they are instructed to locate and eliminate cancer cells.
For patients with specific cancer types, CAR-T cell therapy is a novel treatment option, especially in cases where conventional medicines are ineffective. The treatment has serious hazards that need to be closely watched and managed, even though it gives promise for a long-term remission or even a cure.
